<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03944356</url>
  </required_header>
  <id_info>
    <org_study_id>EUMR-18001</org_study_id>
    <nct_id>NCT03944356</nct_id>
  </id_info>
  <brief_title>BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients</brief_title>
  <acronym>Combi-EU</acronym>
  <official_title>BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients in the Adjuvant Setting: a Non-interventional Observatory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EuMelaReg gGmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EuMelaReg gGmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant therapy with dabrafenib plus trametinib in melanoma was approved in 2018 by the EMA
      (EUropean Medicines Agency).

      The purpose of this non-interventional study is to assess the usage of adjuvant dabrafenib
      and trametinib in clinical practice, where the patient population may differ from study
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melanoma is a disease of significant metastatic potential if not detected very early.
      Oncogenic mutations in BRAF (B-Raf proto-oncogene, serine/threonine kinase) are found in
      approximately 40% of melanomas and result in constitutive activation of the MAPK
      (Mitogen-Activated Protein Kinase) pathway.

      Treatment with the BRAF inhibitor dabrafenib plus the MEK (Mitogen-activated protein kinase
      kinase) inhibitor trametinib showed improved overall survival in patients with unresectable
      or metastatic BRAF V600E/K-mutant melanoma (COMBI-d and COMBI-v studies). In an adjuvant
      setting treatment with dabrafenib and trametinib significantly reduced the risk of melanoma
      recurrence in patients with high-risk, stage III BRAF V600-mutant melanoma, with improvements
      in OS (Overall Survival), DMFS (Distant Metastasis Free Survival), and FFR (Freedom From
      Relaps) (COMBI-AD study). Based on these results, adjuvant dabrafenib plus trametinib therapy
      was approved in 2018 by the EMA.

      Compared to the metastatic situation, issues of compliance and treatment adherence may be
      more relevant in adjuvant treatments, as patients are free of disease and potentially cured
      even without adjuvant treatment. As the routine administration of drugs including dosing,
      treatment interruptions, and early termination in clinical practice may vary from procedures
      defined in clinical trials, this study aims to assess the usage of adjuvant dabrafenib and
      trametinib in the routine clinical setting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Median time on treatment</measure>
    <time_frame>Date of first dose up to 12 months</time_frame>
    <description>Median time on adjuvant dabrafenib + trametinib treatment defined as the interval between start of treatment and permanent discontinuation of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Permanent study drug discontinuation due to any reason</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Rate of permanent study drug discontinuation due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent study drug discontinuation due to adverse drug reactions</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Rate of permanent study drug discontinuation due to adverse drug reactions (ADRs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pyrexia and related symptoms</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Occurrence of pyrexia and related symptoms, listing the grade, number of episodes, and time to resolution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction management: pyrexia</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Type of adverse drug reaction (ADR) management applied for pyrexia and correlation with occurrence/persistence of pyrexia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reactions in Follow-up</measure>
    <time_frame>From date of first treatment until the date of treatment end plus 3 months of follow-up, assessed up to 15 months</time_frame>
    <description>ADRs persisting/emerging up to 3 months post-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Over the course of treatment plus 3 months safety follow up, assessed up to 15 months</time_frame>
    <description>Assessment of health-related quality of life (HRQoL), measured by the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC-QLQ-C30).
The EORTC QLQ-C30 consists of the folowing scales, with each dimension specifying five levels of severity [not at all (level 1), a little (level 2), quite a bit (level 3), very much (level 4)]:
functional scales (Physical, Role, Cognitive, Emotional, Social Functioning)
symptom scales (Fatigue, Pain and Nausea/Vomiting)
single item scales (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties).
Additionally the Global Health Status and QoL scales are incorporated, specifying on a scale from 1 (very poor) to 7 (excellent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Relapse free survival (RFS) time and rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival time</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Distant metastasis free survival (DMFS) time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival rate</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Distant metastasis free survival (DMFS) rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Overall survival (OS) time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Overall survival (OS) rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on treatment and efficacy endpoints</measure>
    <time_frame>From date of first treatment until the date of treatment end, assessed up to 12 months</time_frame>
    <description>Correlation between time on treatment and efficacy endpoints (RFS, DMFS, OS).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib and Trametinib</intervention_name>
    <description>Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.</description>
    <other_name>Tafinlar and Mekinist</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with complete surgical resection of histologically confirmed AJCC (8th
        edition) clinical stage III (IIIA, IIIB, IIIC, IIID) BRAF V600-mutated cutaneous melanoma
        who are planned to be treated or who already started treatment no longer than 4 weeks prior
        to study inclusion with dabrafenib and trametinib under routine conditions according to the
        applying SmPC.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with complete surgical resection of histologically confirmed AJCC (American
             Joint Committee on Cancer) (8th edition) clinical stage III (IIIA, IIIB, IIIC, IIID)
             melanoma, for whom a decision for adjuvant treatment with dabrafenib and trametinib
             has been made before entering the study.

          -  V600E/K mutation-positive cutaneous melanoma

          -  Adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib
             (Mekinist®) as indicated in the SmPC (Summary of Product Characteristics) and by
             prescription, that has been started no longer that 4 weeks before inclusion of the
             patient into the study or which will be initiated directly after inclusion

          -  Age ≥ 18 years

          -  Signed written informed consent

        Exclusion Criteria:

          -  Lack of basic demographics and staging information

          -  Current or planned participation within a clinical trial. The participation in a
             follow-up phase of a clinical trial without active intervention is allowed.

          -  Current or planned treatment of another tumor disease except keratoacanthoma, squamous
             cell or basal cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Elbe Kliniken Stade - Buxtehude GmbH</name>
      <address>
        <city>Buxtehude</city>
        <state>Niedersachsen</state>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Mohr, Dr.</last_name>
      <phone>+49 41617036217</phone>
      <email>Peter.Mohr@elbekliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Schadendorf, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Kiel, Klinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Micheal Weichenthal, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologisches Versorgungszentrum Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10407</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herbert Lebahn, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Susok, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen Mitte gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kjell Kaune, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DRK Krankenhaus Chemnitz Rabenstein</name>
      <address>
        <city>Chemnitz</city>
        <zip>09117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingrid Feldmann-Boeddeker, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund gGmbH</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pia Duecker, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uwe Wollina, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rudolf Herbst, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Arnold, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Gutzmer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Hassel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus-Detlev Klemke, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edgar Dippel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23568</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Terheyden, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Utikal, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Stader, Prof. Dr.</last_name>
      <phone>+49 5717904501</phone>
      <email>rudolf.stadler@muehlenkreiskliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Max Schlaak, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios St. Elisabeth Klinik Oberhausen</name>
      <address>
        <city>Oberhausen</city>
        <zip>46045</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Tigges, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harzklinikum Dorothea Christiane Erxleben GmbH</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Ulrich, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken Schwerin</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaston Schley, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

